Gilman’s Next CEO Trick: Taming CAR-T Cells With Obsidian – Xconomy
|
Gilman's Next CEO Trick: Taming CAR–T Cells With Obsidian
Xconomy Genetically modified medicine is here. Two CAR-T therapies, made from a patient's living T cells, are on the market in the U.S., and many more are in various stages of clinical testing. As remarkable as they might seem, however, these medicines are … |
